WuXi Biologics licences technology to Oxford-based OBT

Shanghai’s WuXi Biologics (HK: 2269) and UK-based Oxford BioTherapeutics (OBT) are to expand their immuno-oncology research collaboration.

OBT, which is focused on immuno-oncology and antibody-drug conjugates, will research, develop and commercialize five novel bispecific antibodies for the treatment of several cancer types using WuXi Biologics' proprietary WuXiBody platform.

WuXi Biologics will receive an upfront payment as well as potential development, regulatory and commercial milestone payments worth up to $450 million, and will be entitled to royalties based on global sales of these bispecific antibodies.